CONMED (CNMD) & Its Competitors Head to Head Contrast

CONMED (NYSE:CNMDGet Rating) is one of 69 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its peers? We will compare CONMED to similar companies based on the strength of its earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and price targets for CONMED and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CONMED 0 0 1 0 3.00
CONMED Competitors 89 601 1659 78 2.71

CONMED presently has a consensus target price of $106.00, indicating a potential upside of 27.48%. As a group, “Electromedical equipment” companies have a potential upside of 91.54%. Given CONMED’s peers higher possible upside, analysts clearly believe CONMED has less favorable growth aspects than its peers.


CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 1.0%. CONMED pays out -27.1% of its earnings in the form of a dividend. As a group, “Electromedical equipment” companies pay a dividend yield of 3.3% and pay out 633.7% of their earnings in the form of a dividend.

Earnings & Valuation

This table compares CONMED and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CONMED $1.01 billion $62.54 million -28.19
CONMED Competitors $1.03 billion $130.62 million 0.72

CONMED’s peers have higher revenue and earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

44.7% of shares of all “Electromedical equipment” companies are owned by institutional investors. 4.9% of CONMED shares are owned by company insiders. Comparatively, 11.3% of shares of all “Electromedical equipment” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares CONMED and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CONMED -7.74% 14.00% 5.24%
CONMED Competitors -694.79% -44.32% -25.31%

Risk & Volatility

CONMED has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, CONMED’s peers have a beta of 13.35, meaning that their average share price is 1,235% more volatile than the S&P 500.


CONMED peers beat CONMED on 8 of the 14 factors compared.

CONMED Company Profile

(Get Rating)

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with's FREE daily email newsletter.